Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3

Introduction Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, provides clinically meaningful improvements in glycaemic control and body weight loss in people with type 2 diabetes. The early efficacy profile of tirzepatide after treatme...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2023-05, Vol.14 (5), p.925-936
Main Authors: Viljoen, Adie, Pantalone, Kevin M., Galindo, Rodolfo J., Cui, Xuewei, Huh, Ruth, Hemmingway, Andrea, Fernández Landó, Laura, Patel, Hiren
Format: Article
Language:English
Subjects:
Antidiabetics
Brief Report
Cardiology
Diabetes
Drug therapy
Endocrinology
Insulin
Internal Medicine
Medicine
Medicine & Public Health
NCT
NCT03882970
NCT03987919
Statistics
Type 2 diabetes
Weight loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, provides clinically meaningful improvements in glycaemic control and body weight loss in people with type 2 diabetes. The early efficacy profile of tirzepatide after treatment initiation is of interest. In this exploratory pre-planned analysis, we evaluated the time to achieve glycaemic control and body weight loss thresholds with tirzepatide. Methods In two randomised studies, we compared time to achieve HbA1c (
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-023-01398-1